XML 26 R17.htm IDEA: XBRL DOCUMENT
v3.26.1

Inventory | 6 Months Ended
--- | ---
Jun. 30, 2026
Inventory Disclosure [Abstract] |
Inventory | 9. Inv entory, net Inventory, net consisted of the following (in thousands):
|  | June 30, 2026 |  |  | December 31, 2025 |
Raw materials |  | $ | 29,201 |  |  | $ | 29,027 |
Work-in-process |  |  | 2,434 |  |  |  | 2,112 |
Finished goods |  |  | 1,529 |  |  |  | 1,615 |
Total Inventory, net |  | $ | 33,164 |  |  | $ | 32,754 |
Inventories are stated at the lower of cost or net realizable value, as determined on a first-in, first-out basis. Prior to the FDA's approval of Revuforj in November 2024, all costs for the manufacturing of product to support clinical development and commercial launch, including pre-launch inventory, were expensed as research and development costs. The pre-launch inventory will continue to be used in commercial production until it is depleted.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration